

This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

April 30, 2025

To whom it may concern:

| | |
|----------------|---|
| Company | D.Western Therapeutics Institute, Inc. |
| Representative | Yuichi Hidaka, President and CEO (Code No. 4576) |
| Contact | Sayako Matsubara, Director |
| TEL | 052-218-8785 |

Announcement of joint research agreement with Mie University for the development of new drugs for lifestyle-related diseases targeting our compounds

We are pleased to announce that today we have entered into a joint research agreement with Mie University, a national university corporation, to create new drugs for lifestyle-related diseases.

In this joint research project, we will utilize low-molecular-weight compounds developed by our company, and Yasuhito Shimada, representative of the Zebrafish Research Center at Mie University, will evaluate their efficacy using zebrafish models of lifestyle-related diseases.

Zebrafish are fish, but they have almost the same number of genes as humans, and their major organs and tissues develop and are structured like humans. Additionally, the process by which fertilized eggs differentiate and form various organs can be observed through their transparent bodies, enabling the visualization of biomolecules within the body by binding them with fluorescent substances. Furthermore, compared to animal testing using rodents such as mice, it is estimated that the number of compounds required per compound is less than one-thousandth, making the method of using zebrafish as an evaluation animal, known as “zebrafish screening,” an efficient screening technique employed in the new drug development process.

Our company has a proven track record in creating kinase inhibitors and has demonstrated its technical capabilities primarily in ophthalmology. However, given the demonstrated efficacy of kinase inhibitors in many disease areas, we will promote this joint research to maximize the potential of our proprietary compounds.

Due to this matter, there will be no change to the earnings forecast for the fiscal year ending December 2025.

End